The business case for human-centred clinical trials.
Business Reporter 458 Md Group Content Final Cut Af
Pharmaceutical and biotech companies invest billions of dollars developing new treatments, yet many clinical trials face a costly and persistent challenge: patient dropout.
While discussions often focus on recruitment, retention can be just as critical to study success. Patients who leave a trial early can impact timelines, increase costs, reduce statistical power and delay the delivery of potentially life-changing therapies.
The question is often asked: why do patients drop out?
The answer is usually far more practical than many people realise.
Clinical trial participants are not simply patients. They are parents, caregivers, employees, students and individuals managing complex lives alongside their health conditions.…